These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35876949)

  • 1. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
    Wang S; Chen S; Zhong Q; Liu Y
    J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
    Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
    Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
    Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
    Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
    Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
    Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatiotemporal homogeneity and distinctness of the T-cell receptor β-chain repertoires in Epstein-Barr virus-associated primary and metastatic nasopharyngeal carcinomas.
    Chung YL; Wu ML
    Int J Cancer; 2018 Aug; 143(3):610-620. PubMed ID: 29468660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Yeo BSY; Lee RS; Lim NE; Tan E; Jang IJH; Toh HC; Lim CM
    Oral Oncol; 2024 May; 152():106786. PubMed ID: 38615584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
    Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
    JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic approaches in nasopharyngeal carcinoma.
    Chow JC; Ngan RK; Cheung KM; Cho WC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
    Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
    Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
    Juarez-Vignon Whaley JJ; Afkhami M; Onyshchenko M; Massarelli E; Sampath S; Amini A; Bell D; Villaflor VM
    Curr Treat Options Oncol; 2023 Sep; 24(9):1138-1166. PubMed ID: 37318724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.
    Tsang CM; Tsao SW
    Virol Sin; 2015 Apr; 30(2):107-21. PubMed ID: 25910483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
    Lee AZE; Tan LSY; Lim CM
    Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
    Louis CU; Straathof K; Bollard CM; Ennamuri S; Gerken C; Lopez TT; Huls MH; Sheehan A; Wu MF; Liu H; Gee A; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
    J Immunother; 2010; 33(9):983-90. PubMed ID: 20948438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
    Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
    Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal dynamics of tumor-infiltrating T-cell receptor beta-chain repertoires in the peripheral blood in response to concurrent chemoradiotherapy for Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Chung YL; Wu ML
    Oncoimmunology; 2021; 10(1):1968172. PubMed ID: 34513316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
    Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
    Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
    Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
    Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.